MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$223K
EPS
$0.01
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development expenses
40
37
309*
73
General and administrative expenses
159
186
86*
178
Operating loss
-199
-223
-395*
-251
Total financial expense
-24
-6
-17*
-4
Net loss
-223
-229
-413
-255
Basic EPS
0.01
0.01
-0.021
0.01
Diluted EPS
0.01
0.01
-0.021
0.01
Basic Average Shares
20,176,418
20,176,418
19,402,321
19,626,418
Diluted Average Shares
20,176,418
20,176,418
19,402,321
19,626,418
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$223K
(30.75%↑ Y/Y)
Operating loss
-$199K
(36.83%↑ Y/Y)
Total financial
expense
-$24K
(-242.86%↓ Y/Y)
General and
administrative expenses
$159K
(-8.62%↓ Y/Y)
Research and development
expenses
$40K
(-71.63%↓ Y/Y)
Buy us a coffee
Raphael Pharmaceutical Inc. (RAPH)
Raphael Pharmaceutical Inc. (RAPH)